• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LivaNova PLC filed SEC Form 8-K: Regulation FD Disclosure

    5/21/25 4:08:06 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email
    livn-20250515
    LIVANOVA PLC0001639691false00016396912025-05-152025-05-15

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 15, 2025

    livanova8ktemplat_image.jpg
    LivaNova PLC
    (Exact Name of Registrant as Specified in its Charter)
    England and Wales001-3759998-1268150
    (State or Other Jurisdiction
     of Incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

    20 Eastbourne Terrace
    London, W2 6LG
    United Kingdom
    (Address of Principal Executive Offices)

    +44 20 33250660
    (Registrant’s Telephone Number, Including Area Code)

    N/A
    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name on each exchange on which registered
    Ordinary Shares - £1.00 par value per shareLIVNNASDAQ Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    ☐



    Item 7.01 Regulation FD Disclosure.

    As previously disclosed, LivaNova PLC (the “Company”) has been engaged in a civil action whereby the Court of Appeal of Milan (the “Court of Appeal”) previously declared the Company (formed through a merger with Sorin) jointly and severally liable with SNIA (a former parent of Sorin) for environmental liabilities incurred by SNIA’s other subsidiaries. On March 14, 2025, the Italian Supreme Court issued its decision in response to all of the appeals of the Company and counter-appeals submitted by the Ministry of Ecological Transition, the Ministry of Economy and Finance, and the Prime Minister’s Office (collectively, the “Ministry”), and referred the case back to the Court of Appeal to implement the decisions respecting costs and damages in accordance with its judgment. As a result of the decision by the Italian Supreme Court, the Company recorded a current liability of €333.3 million ($360.4 million) as of and for the three months ended March 31, 2025 as its best estimate of the liability inclusive of estimated costs, fees, interest, and taxes.

    On May 15, 2025, as a procedural step outlined above, the Ministry served the Company with a filing to return the proceedings to the Court of Appeal. In addition to seeking return of the case to the Court of Appeal, the Ministry asserted that the Court of Appeal forego an examination of the amounts disapproved by the Italian Supreme Court and instead impose costs of approximately €108.8 million at a minimum. These assertions are counter to the decision of the Italian Supreme Court’s judgment, which disapproved costs of €157.3 million ($170.0 million as of March 31, 2025). The Ministry also requested a hearing in 2026 in connection with the foregoing.

    The Ministry’s filing is not a legal judgment or demand for payment. The Company disagrees with the assertions made in the Ministry’s filing and believes they contradict the decisions of the Italian Supreme Court. The Company intends to challenge the Ministry’s assertions and purported costs and to defend its position in accordance with the Italian Supreme Court’s judgment. The Company continues to believe that its recorded liability remains the best estimate of the liability associated with the SNIA matter, and, as such, no adjustments have been made to the accrual or the Company’s full-year 2025 guidance in response to this development.

    Certain statements in this Current Report on Form 8-K, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act including statements regarding the status and timing of final resolution of the Company’s SNIA litigation and the projected impact of the SNIA litigation on the Company’s financial results. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. Generally, forward-looking statements can be identified by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by the Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the U.S. Securities and Exchange Commission by the Company. Readers are cautioned not to place undue reliance on the Company’s forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update publicly any of the forward-looking statements in this Current Report on Form 8-K to reflect actual results, new information or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If the Company updates one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.




    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    LivaNova PLC
    Date: May 21, 2025
    By: /s/ Michael Hutchinson
    Name: Michael Hutchinson
    Title: SVP, Company Secretary & Chief Legal Officer


    Get the next $LIVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    10/1/2025$55.00Buy → Neutral
    Goldman
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    9/6/2023$52.00Hold
    HSBC Securities
    More analyst ratings

    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LivaNova downgraded by Goldman with a new price target

    Goldman downgraded LivaNova from Buy to Neutral and set a new price target of $55.00

    10/1/25 8:42:07 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00

    5/20/25 8:01:26 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova downgraded by Wolfe Research

    Wolfe Research downgraded LivaNova from Outperform to Peer Perform

    2/26/25 7:12:54 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC

    SCHEDULE 13G/A - LivaNova PLC (0001639691) (Subject)

    11/6/25 4:19:28 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form IRANNOTICE filed by LivaNova PLC

    IRANNOTICE - LivaNova PLC (0001639691) (Filer)

    11/5/25 12:28:08 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by LivaNova PLC

    10-Q - LivaNova PLC (0001639691) (Filer)

    11/5/25 12:26:10 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Story Brooke sold $13,485 worth of Ordinary Shares (250 units at $53.94), decreasing direct ownership by 4% to 6,232 units (SEC Form 4)

    4 - LivaNova PLC (0001639691) (Issuer)

    11/19/25 3:57:02 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Zurbay Donald

    4 - LivaNova PLC (0001639691) (Issuer)

    9/17/25 4:08:20 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President, Cardiopulmonary Poletti Franco converted options into 643 units of Ordinary Shares and covered exercise/tax liability with 277 units of Ordinary Shares, increasing direct ownership by 5% to 8,299 units (SEC Form 4)

    4 - LivaNova PLC (0001639691) (Issuer)

    9/17/25 4:05:35 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

    Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. "At the heart of LivaNova's purpose as a Company, we aim to help patients reclaim their lives by improving global access t

    12/3/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. "Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector," Makatsaria said. "With her extensive OSA market expertise, she has a strong track record in creating new sleep therapy pathways, improving patient access to care, and building strong commercial teams. Her leadership will help us unlock transformational growth by co

    12/2/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova to Present at Piper Sandler Healthcare Conference in December

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup of the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation.

    11/25/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Leadership Updates

    Live Leadership Updates

    View All

    LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. "Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector," Makatsaria said. "With her extensive OSA market expertise, she has a strong track record in creating new sleep therapy pathways, improving patient access to care, and building strong commercial teams. Her leadership will help us unlock transformational growth by co

    12/2/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Donald Zurbay as a New Director

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of Directors, effective today. Zurbay will serve on the Audit and Compliance Committee for the Board. "LivaNova is pleased to welcome Don to our Board of Directors," said William Kozy, Chair of the Board. "Over the course of 30 years, he has amassed expertise in finance, accounting, and strategy, much of which he honed while serving in leadership positions with global healthcare companies. His deep experience and knowledge will be welcome assets to the Board." Zurbay joins the LivaNova Board of Directors after a seven-year tenure at Patterson C

    9/4/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

    1/6/25 9:00:00 AM ET
    $ABT
    $BMY
    $IRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $LIVN
    Financials

    Live finance-specific insights

    View All

    LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

    – Delivered double-digit reported and organic revenue growth and continued operating margin expansion – Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1) – Launched Essenz Perfusion System in China LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an organic basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per sh

    11/5/25 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova to Announce Third-Quarter 2025 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5, 2025, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 817099. A replay will be available on th

    10/8/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

    Delivered double-digit reported and organic revenue growth and continued operating margin expansion Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1) Initiated process with U.S. Centers for Medicare and Medicaid Services for reconsideration of national coverage for VNS Therapy™ for treatment-resistant depression Announced long-term, real-world evidence demonstrating efficacy of VNS Therapy in a wide range of seizure types in people with drug-resistant epilepsy LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2025 and raised full-year 2025 guidan

    8/6/25 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LivaNova PLC

    SC 13G - LivaNova PLC (0001639691) (Subject)

    4/17/24 4:19:05 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    2/12/24 4:01:13 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    1/23/24 11:52:27 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care